Navigation Links
China Nepstar Chain Drugstore to Announce First Quarter 2009 Financial Results on Wednesday, May 27, 2009
Date:5/12/2009

SHENZHEN, China, May 12 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("China Nepstar" or the "Company"), the largest drugstore chain in China based on the number of directly operated stores, announced today that the company will report the first quarter financial results ended March 31, 2009, before the market opens on Wednesday, May 27, 2009.

The Company will host a conference call, to be simultaneously Web cast, on Wednesday, May 27, 2009 at 8:00 a.m. Eastern Daylight Time / 8:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five to ten minutes before the call start time. A live Web cast of the conference call will be available on the Nepstar Web site at http://www.nepstar.cn .

A replay of the call will be available starting on May 27, 2009, at 11:00 a.m. Eastern Daylight Time / 11:00 p.m. Beijing Time through June 6, 2009 at 11:59 p.m. Eastern Daylight Time or June 4, 2009 at 11:59 a.m. Beijing Time. An archived Web cast of the conference call will be available on the Nepstar Web site at http://www.nepstar.cn . Interested parties may access the replay by dialing +1-877-660-6853 (North America) or + 1-201-612-7415 (International) and entering account number 286 and conference ID number 323198.

About China Nepstar Chain Drugstore Ltd.

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain based on the number of directly operated stores. As of December 31, 2008, the Company had 2,709 stores across 76 cities (including 355 stores of Yunnan subsidiary, which ceased to be the Company's subsidiary in January 2009), one headquarters distribution center and 11 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the robust economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn .

    For more information, please contact:

    In China:
     Lucia Qian
     China Nepstar Chain Drugstore Ltd.
     Marketing and IR Director
     Tel:   +86-755-2641-4065
     Email: qianrt@nepstar.cn

    In the United States:
     Dixon Chen
     Grayling
     Investor Relations
     Tel:   +1-646-284-9403
     Email: Dixon.chen@us.grayling.com

     Ivette Almeida
     Grayling
     Media Relations
     Tel:   +1-646-284-9455
     Email: Ivette.almeida@us.grayling.com

'/>"/>
SOURCE China Nepstar Chain Drugstore Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New study reveals the financial effects of stroke in China
2. China Pharma Holdings, Inc. to Report First Quarter 2009 Financial Results on May 15, 2009
3. China Medicine Announces Conference Call to Discuss First Quarter 2009 Results
4. China Medicine to Present at CCG IRs China Rising Conference in New York
5. IBM Announces New Healthcare Industry Solutions Lab in China
6. Solta Medical Receives Regulatory Approval to Market Thermage Systems in China
7. China Pharma Holdings, Inc. Retains Global Investor Communications Team
8. goBalto Partners With ChinaBio to Expand Its List of Contract Research Organizations
9. China Pharma Holdings, Inc. Appoints Chief Financial Officer and Board Member
10. Milestone Scientific Grants Sinopharm Exclusive Distribution and Marketing Rights to STA System in China
11. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... School of Nursing with an in-kind gift of a VeinViewer® Vision vein ... as they learn how to start an IV and draw blood, combining technology ...
(Date:2/13/2016)... Montreal, Canada (PRWEB) , ... February 13, 2016 , ... ... best foot forward. They’ll groom themselves to perfection, go out of their way to ... their date – just take a look at any online dating profile. , ...
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... ... The law firm of Morrow, Morrow, Ryan & Bassett is offering scholarships to ... to encourage applicants to pursue a degree in their field of study and upon ... “We have available jobs in St. Landry and Evangeline Parishes that can be filled ...
(Date:2/12/2016)... ... 12, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. The special ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... 12 2016  OMS Supply, a large provider of ... announced today the recent launching of their new company ... of features that enhance the user experience and enable ... --> --> Despite ... company that started in early 2016, they have already ...
(Date:2/12/2016)... Feb. 12, 2016  Apellis Pharmaceuticals, Inc., ... $47.1 million Series D preferred stock financing, ... Hillhouse Capital Group and venBio Global Strategic ... AJU IB Investment, and Epidarex Capital. The proceeds ... further advance clinical trials in the Company,s ...
Breaking Medicine Technology: